| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squ NCT07156227 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Nec NCT06868433 | Emory University | Phase 1 |
| Recruiting | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returni NCT06589804 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Recruiting | Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, NCT06636734 | Emory University | Phase 2 |
| Active Not Recruiting | Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy NCT05063552 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) NCT05172258 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Tr NCT04576091 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Combining Immunotherapy Salvage Surgery & IORT Tx Persistent/Recurrent Head & Neck Cancer NCT04754321 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcin NCT04862650 | Marcelo Bonomi | Phase 2 |
| Recruiting | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treat NCT04671667 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery NCT04588038 | Hyunseok Kang, MD | Phase 1 |
| Active Not Recruiting | Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer NCT03468218 | Emory University | Phase 2 |
| Completed | Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Can NCT03032250 | Wake Forest University Health Sciences | N/A |
| Terminated | Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer NCT02388932 | Case Comprehensive Cancer Center | N/A |
| Terminated | Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer NCT02068157 | Roswell Park Cancer Institute | Phase 2 |
| Terminated | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Ne NCT02196168 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer NCT01254617 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer NCT01267240 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who D NCT01256385 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recur NCT01064479 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer NCT02007200 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squam NCT00588770 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent NCT00494182 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer NCT00458978 | National Cancer Institute (NCI) | Phase 2 |